Developing science,
delivering therapies


Our company

We are pioneers in harnessing bacteria as a revolutionary new class of medicines – called live biotherapeutics.

Our approach

Developing science

From asthma to cancer, we conduct world-leading research to identify live biotherapeutics with drug-like functionality to treat a range of diseases.

What we do

Delivering therapies

We are uniquely positioned to rapidly translate our research into regulated, safe and efficacious therapies for patients.

Find out more


4D commences treatment of the first patients in Part B of its Phase I/II clinical trial of MRx0518 in combination with immune checkpoint inhibitor Keytruda® (pembrolizumab) in patients with acquired resistance to prior immune checkpoint therapy.
Phase II study of MRx-4DP0004 in patients hospitalized with COVID-19 open for enrolment. Dosing of first patients expected to commence shortly.
4D's Chairman, CEO and CSO provide updates on the company’s clinical programmes in oncology and COVID-19